An APLA test in pregnancy checks for antiphospholipid antibodies—lupus anticoagulant, anticardiolipin, and anti–β2 glycoprotein I. These antibodies raise the risk of blood clots, recurrent miscarriage, stillbirth, preeclampsia and fetal growth restriction. Diagnosis usually requires persistently positive results at least 12 weeks apart. If positive, treatments like low‑dose aspirin and heparin can lower complication risk.

APLA testing includes: lupus anticoagulant assays (functional coagulation tests such as dilute Russell’s viper venom time with mixing/confirmatory steps), anticardiolipin antibodies (IgG and IgM), and anti–β2‑glycoprotein I antibodies (IgG and IgM). For diagnosis, positive results must be persistent on repeat testing at least 12 weeks apart to exclude transient antibodies.

The APLA (antiphospholipid antibody) profile detects antibodies — lupus anticoagulant, anticardiolipin, and anti–β2 glycoprotein I — to diagnose antiphospholipid syndrome. It’s used for unexplained blood clots, recurrent miscarriages or pregnancy complications, and to guide anticoagulation decisions. Tests are usually repeated 12 weeks apart to confirm persistence and inform treatment and risk-reduction.

The APLA test is best when there’s clinical suspicion of antiphospholipid syndrome — after unexplained thrombosis or pregnancy loss. Initial testing can be done anytime, but positives must be repeated at least 12 weeks later to confirm persistence (avoid transient results during acute infection). Lupus‑anticoagulant assays may be affected by anticoagulants, so time testing with your clinician if stopping therapy is safe.

If an antiphospholipid (APLA) test is positive, it signals increased risk of blood clots and pregnancy complications. Repeat testing after 12 weeks is required to confirm persistence. Clinical assessment determines whether antiphospholipid syndrome is diagnosed. Management may include specialist referral and preventive treatment such as low-dose aspirin, heparin in pregnancy, or long-term anticoagulation, plus close monitoring and risk-factor reduction.

Costs for antiphospholipid (APLA) testing in pregnancy vary by country and provider. On the UK NHS the test is provided when clinically indicated; privately it typically costs about £60–£200. In the United States expect roughly $100–$500 for a panel. In India prices commonly range ₹500–3,000. Labs may charge per antibody, so a full panel can cost more; confirm with your local lab.